Parathyroid hormone (PTH), acting through the PTH receptor (PTHR1), expressed in bone and kidney, plays a vital role in maintaining proper blood levels of calcium and phosphate, and also contributes to the regulation of bone growth and remodeling. PTHrP, acting through the same PTHR1, regulates the development of the skeleton and other tissues. Drugs that target the PTHR1 are of interest because they could potentially be used to treat human diseases, such as osteoporosis and hypoparathyroidism (HPT). Yet PTH(1-34) is the only FDA-approved PTH-based therapy. It is thus used to treat osteoporosis, and, while effective, must be injected once a day. The proposed studies will define the molecular mechanisms by which PTH ligands bind to and activate the PTHR1. They will generate new types of PTH analogs, including signaling selective analogs and novel long-acting ligands that are structurally more stable or have adducts that impair renal clearance, and will assess these analogs for binding to the PTHR1 in vitro, and for actions in animals. Also explored will be new non-peptidic, small-molecule ligands for the PTHR1. Selected ligands will be evaluated in a mouse model of HPT (PTH-null mice) for their capacity to normalize blood calcium. New long-acting PTH analogs will also be tested for their capacities to stimulate bone formation and improve strength when injected into mice at low-frequency intervals, such as once-weekly, and in a dual-therapy mode with the bone-resorption inhibitor, OPG-FC.

Public Health Relevance

The proposed studies will lead to a better understanding of how PTH ligands bind to and activate the PTHR1. They will also provide clues for. how to develop and utilize new PTH ligand analogs for more effective treatment of diseases such as osteoporosis and hypoparathyroidism.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Grigelioniene, Giedre; Nevalainen, Pasi I; Reyes, Monica et al. (2017) A Large Inversion Involving GNAS Exon A/B and All Exons Encoding Gs? Is Associated With Autosomal Dominant Pseudohypoparathyroidism Type Ib (PHP1B). J Bone Miner Res 32:776-783
Roszko, Kelly L; Bi, Ruiye; Gorvin, Caroline M et al. (2017) Knockin mouse with mutant G?11 mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors. JCI Insight 2:e91079
Mitchell, Deborah M; J├╝ppner, Harald; Burnett-Bowie, Sherri-Ann M (2017) FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls. J Clin Endocrinol Metab 102:1151-1160
Li, Yuwen; Caballero, Daniel; Ponsetto, Julian et al. (2017) Response of Npt2a knockout mice to dietary calcium and phosphorus. PLoS One 12:e0176232
Leaf, David E; Jacob, Kirolos A; Srivastava, Anand et al. (2017) Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. J Am Soc Nephrol 28:1877-1885
Knab, Vanessa M; Corbin, Braden; Andrukhova, Olena et al. (2017) Acute Parathyroid Hormone Injection Increases C-Terminal but Not Intact Fibroblast Growth Factor 23 Levels. Endocrinology 158:1130-1139
Guo, Jun; Khatri, Ashok; Maeda, Akira et al. (2017) Prolonged Pharmacokinetic and Pharmacodynamic Actions of a Pegylated Parathyroid Hormone (1-34) Peptide Fragment. J Bone Miner Res 32:86-98
Balani, Deepak H; Ono, Noriaki; Kronenberg, Henry M (2017) Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J Clin Invest 127:3327-3338
Kim, Sang Wan; Lu, Yanhui; Williams, Elizabeth A et al. (2017) Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts. J Bone Miner Res 32:892-901
Ono, Noriaki; Kronenberg, Henry M (2016) Bone repair and stem cells. Curr Opin Genet Dev 40:103-107

Showing the most recent 10 out of 208 publications